Table 7:
Hearing Targeted Early CMV Testing Studies
Reference | Number of patients with failed NBHS | # Tested for cCMV (% = # tested/# failed NBHS) | #cCMV positive (% positive) | #SNHL/#cCMV positive (%) |
---|---|---|---|---|
Current Study | 11,118 | 9017 (81.1%) | 132 (1.5%) | 53/132 (39%) |
Fowler et. (2017) 17 | 999 | 999 (100%)1 | 31 (3.1%) | 20/31 (65%) |
Ari-Even et al (2016)21 | 200 | 187 (93.5%) | 4 (2.3%) | 3/4 (75%) |
Williams et al (2014)22 | 411 | 404 (98%)2 | 6 (1.5%) | 3/6 (50%) |
Beswick et al (2019)23 | 283 | 234 (83%) | 3 (1.3%) | 2/3 (67%) |
Diener et al (2017)24 | 509 | 234 (61.7%) | 14 (6%) | 4/14 (67%) |
Raynor et al (2021)25 | 444 | 38 (8.5%) | 2 (5.3%) | 2/2 (100%) |
Ronner et al (2022)26 | 891 | 530 (60%) | 8 (1.5%) | 3/5 (75%)3 |
Vancor et al (2019)31 | 171 | 171 (100%) | 2 (1.2%) | 1/2(50%) |
Fourgeaud et al (2022)32 | 236 | 231 (98%) | 2 (0.8%) | 2/2 (100%) |
Webb et al (2022)33 | 126 | 96 (76.2%) | 1 (1%) | 1/1 (100%) |
Yamamoto et al (2020)34 | 91 | 91 (100%)1 | 7 (7.7%) | 7/7 (100%) |
Stehel et al (2008)88 | 572 | 483 (84%) | 24 (5%) | 16/24 (67%) |
Total (Exclude Current Study) | 4933 | 3698 (75%) | 104 (2.8%) | 64/101 (63.3%) |
Part of a universal CMV study
Testing rate affected by need for parental consent, having them perform the testing and returning samples
Approximation based on data presented